Sensitivity of T-Wave Morphology and the QT Interval to Small Drug-Induced Electrocardiographic Changes

C Graff¹, J Matz², MP Andersen¹, JK Kanters³,4, E Toft¹, S Pehrson⁵, JJ Struijk¹

¹Department of Health Science and Technology, Aalborg University, Aalborg, Denmark
²H Lundbeck A/S, Copenhagen, Denmark
³Danish National Research Foundation Centre for Cardiac Arrhythmia (DARC), University of Copenhagen, Copenhagen, Denmark
⁴Department of Cardiology P, Gentofte University Hospital, Copenhagen, Denmark
⁵Department of Cardiology B, Rigshospitalet, Copenhagen, Denmark

Abstract

The electrocardiographic QT interval is the only widely used surrogate marker of repolarization abnormality in drug trials. However, numerous basic and clinical studies have provided evidence that disturbed ventricular repolarization is reflected not only in the duration of the QT interval but also in the shape of the electrocardiographic T-wave. Thus, in order to elucidate the full spectrum of drug-induced repolarization changes, it is pertinent to perform a thorough analysis of T-wave morphology changes in addition to measuring the QT interval.

We present a computerized method for quantification of drug-induced T-wave morphology changes. Our results provide evidence that the shape of the T-wave can be a more sensitive marker of disturbed repolarization than QT interval prolongation. Effect sizes for T-wave morphology changes, 1.58±0.30 (mean±SD) were 1.8 times larger than those for QTcF, 0.87±0.14, p=0.0013.

1. Introduction

In recent years there has been a raised awareness regarding the cardiovascular safety of drugs and several drugs have been withdrawn from the market because they have been associated with the risk of developing cardiac arrhythmias [1, 2]. Most drugs that cause disturbed repolarization and arrhythmias inhibit the I_Kr current and have a QT prolonging effect [3]. As a consequence, the electrocardiographic QT interval is presently used as the golden standard by which cardiac safety is assessed in “Thorough QT Studies”. However, much smaller than expected QT prolongations have been reported in patients with drug-induced arrhythmias [4, 5] and important abnormalities of the repolarization sequence may not be identified by the QT interval, which characterizes only the total duration of depolarization and repolarization. Indeed, it was recently shown that abnormally shaped T-waves frequently appear without overt QT prolongation in a population of congenital LQT2 patients [6]. In addition, there are limitations to the ability to reliably detect small changes in the QT interval (<5% of the interval) [7, 8].

Other ECG indices may therefore contribute importantly to assessment of drug-induced repolarization changes. Our previous work has shown that measures of T-wave morphology can be used to discriminate between LQT1, LQT2 and healthy subjects [9, 10]. Recognizing that a direct link has been established between inherited and drug-induced Long QT Syndrome we hypothesize that abnormal T-wave morphologies like those described in the congenital LQTS would identify small drug-induced repolarization changes with a greater sensitivity than the QT interval.

2. Methods

2.1. Study population and design

Seventy-nine healthy subjects (age: 18-45 y, mean±SD 28±8 y) were included in the study. Healthy status was confirmed by history, physical examination, normal blood pressure and no use of concomitant medication. All subjects gave informed consent.

After a baseline day (day -1) where no drug was given, forty subjects (16 females, 24 males) received a single oral dose of an investigational I_Kr inhibiting anti-psychotic compound (Lu 35-138) on seven consecutive
days (day 1 to day 7) while thirty-nine subjects (15 females, 24 males) received placebo.

2.2. ECG recordings

Three successive 12-lead resting ECGs of 10 s duration were recorded for each subject at 0, 2, 4, 6 and 12 h post-dose on the final study day (day 7) and at corresponding times on the baseline day (day -1).

2.3. ECG processing

Each 10 s ECG was used to form a median beat in the recorded leads using MUSE/Interval Editor software (GE Healthcare, Milwaukee, WI). Principal Component Analysis (PCA) was used to compute principal component median beats from the median beats in leads (I, II, V1-V6). The first principal component T-wave was used to calculate combined measure of repolarization morphology (MCS), based on asymmetry, flatness and notching. Fiducial point detection and QT measurements (Fridericia corrected, QTcF) were made automatically using the 12SL algorithm (12SL, GE Healthcare, Milwaukee, WI).

2.4. T-wave morphology measures

Three measures of T-wave morphology were used to identify drug-induced shape changes of the T-wave. The morphology measures were developed in earlier studies to describe the differences in T-wave asymmetry, flatness and notching between healthy subjects as representatives of normal repolarization and LQT2 subjects as a biological model of I_{Kr} channel inhibition [11].

Asymmetry:

The difference in slope profiles of the ascending and descending parts of the T-wave was considered a measure of asymmetry. The slopes at each point of the descending part of the T-wave were mirrored to be compared with the slopes at corresponding points of the ascending segment. Both segments were normalized with the maximum of the derivative within each segment. Asymmetry was defined as the average squared difference (d) between the slope segments, equation 1.

$$\text{Asymmetry} = \frac{\sum_{n=1}^{N} d(n)^2}{N}$$

Notch:

A curvature signal was obtained from the first and second derivatives of T-waves, equation 2.

$$\text{Curvature} = -\frac{\frac{d^2y}{dx^2}}{\left[1 + \left(\frac{dy}{dx}\right)^2\right]^{3/2}}$$

Deflections in curvature were used to indicate the presence or absence of notches on the T-wave. The magnitude of a notch was measured on a unit amplitude T-wave and assigned to 1 of 3 categories as previously suggested [12]: No notch = 0, moderate notch (perceptible bulge) = 0.5 and pronounced notch = 1.0 (distinct protuberance above the apex).

Flatness:

Flatness was calculated as a modified version of the standard kurtosis measure which is used statistics to describe the peakedness of a probability distribution. The T-wave was normalized to unit area and central moments were calculated using equation 3.

$$M_k = \left[\sum_{n=1}^{N} (n-M_c)\text{ECG}(n)\right]^2, \quad M_4 = \sum_{n=1}^{N} \text{ECG}(n)$$

The fourth central moment ($M_4$) was normalized with the squared second moment ($M_2$) and subtracted from one to let increasing values of flatness reflect increasing flatness of the T-wave, equation 4.

$$\text{Flatness} \approx 1 - \frac{M_4}{M_2^2}$$

Morphology Combination Score (MCS):

The three morphology measures were standardized by their relative variances and a linear combination was calculated to yield an overall description of T-wave morphology, equation 5.

$$\text{MCS} = \text{Asymmetry} + \text{Notch} + 1.6 \cdot \text{Flatness}$$

2.5. Effect size measures

Effect sizes for MCS and the Fridericia corrected QT interval (QTcF) were computed on the final study day as the time matched (0, 2, 4, 6 and 12 h post-dose) placebo corrected changes of means ($\mu$) from baseline expressed in number of standard deviations ($\sigma$), equation 6.

$$\text{Effect size} = \frac{(\mu_{T,post} - \mu_{T,pre}) - (\mu_{C,post} - \mu_{C,pre})}{\sigma_{\text{Pooled,pre}}}$$

where the subscripts $T$ and $C$ indicate the treatment group and the control group respectively.

Given that effect sizes are standardized, they allow direct comparison of the magnitude of change in MCS.
and QTcF to see if one measure is more sensitive to detecting disturbed repolarization than the other.

3. Results

Administration of the I\textsubscript{Kr} channel inhibiting investigational antipsychotic drug (Lu 35-138) caused prolongation of the mean QTcF and distinct morphological changes in T-wave asymmetry, flatness and the degree and presence of notches, figure 1.

In general the electrocardiographic T-waves in the treatment group were characterized by a longer duration of the ascending part of the T-wave and a noticeable decrease in the slope of that segment, leading to the appearance of asymmetric T-waves, figure 2.

The development of a broader base and decreasing amplitude increased the flatness of T-waves. There were 6 subjects who developed notched T-waves after Lu 35-138 was given, whereas no notches were identified in the placebo group. I-bars indicate mean±1SE.

There was a significant prolongation of the mean placebo corrected (pc: \( \Delta \text{treatment} - \Delta \text{placebo} \)) QTcF (QTcF\textsubscript{pc}) at study time 0 h on day 7, 11 ms [95% CI: 8 to 13 ms], \( p<0.001 \). At this study time a significant increase in the mean placebo corrected MCS (MCS\textsubscript{pc}) was also found, 0.14 [95% CI: 0.11 to 0.17], \( p<0.001 \). The QTcF\textsubscript{pc} prolongations increased after dose from 11 ms (0 h) to 18 ms (4 and 6 h) [95% CI: 15 to 21 ms], \( p<0.001 \). The MCS\textsubscript{pc} increased from 0.14 (0 h) to 0.23 (6 h) [95% CI: 0.18 to 0.27], \( p<0.001 \).

Overall, the time matched, placebo corrected effect sizes for MCS on day 7 were almost twice the effect sizes for QTcF.

The difference between effect sizes for QTcF\textsubscript{pc} and MCS\textsubscript{pc} did not reach significance before dose was given on day 7 (0 h), 0.44 [95% CI: -0.01 to 0.89], \( p=0.057 \), figure 3. Post-dose, the effect sizes for MCS\textsubscript{pc} increased significantly more than the effect sizes for QTcF\textsubscript{pc}, figure 3. At 6 h post-dose, the effect size difference between MCS\textsubscript{pc} and QTcF\textsubscript{pc} reached 0.93 [95% CI: 0.34 to 1.53], \( p<0.01 \). At this study time, an additional 17 ms prolongation of the mean placebo corrected QTcF would have been required for QTcF\textsubscript{pc} and MCS\textsubscript{pc} effect sizes to be similar.

Figure 2. Time matched T-wave differences between baseline and final study day in one subject. There was an increasing prolongation of QTcF after dose and the T-wave developed an increasingly distinct asymmetric and flat appearance.

Figure 3. There was a significantly greater drug effect on T-wave morphology compared with QTcF. The time matched, placebo corrected effect sizes for MCS on day 7 were almost twice the effect sizes for QTcF.
4. Discussion and conclusions

The results of the present study suggest that it may be possible to identify drug-induced repolarization changes using computerized measures of T-wave morphology patterns that are characteristic of congenital LQT2. It was also shown that drug effects on repolarization morphology can be greater than the corresponding effect on the QT interval.

These findings could have important implications for future drug studies. First, it is widely recognized that QT interval prolongation is not the core of the problem with drugs causing arrhythmias. Most drugs are proarrhythmic because they increase inhomogeneity of repolarization. It is therefore imperative to identify electrocardiographic markers that describe cellular level inhomogeneity. Whether a drug-induced change in the morphology of the T-wave can be used as a better surrogate marker of repolarization inhomogeneity than the QT interval, remains to be investigated. However, as a first step in the search for improved electrocardiographic markers of repolarization inhomogeneity, emphasis must be put on the sensitivity of new surrogate markers to small drug-induced repolarization changes. Our results indicate that the degree of T-wave asymmetry, flatness and notching might be used as a more sensitive overall description of small drug-induced changes than the QT interval.

Second, most drugs that cause QT prolongation and abnormal T-waves affect the HERG channel as in congenital LQT2. Electrocardiographic expressions of abnormal repolarization in LQT2 patients would therefore be expected to be directly applicable to the identification of drug-induced repolarization changes.

We believe that computerized measures of T-wave morphology would be an important addition to QT interval measurements because such measures may contribute to an expanded ECG safety evaluation in future drug studies through more careful characterization of repolarization abnormalities.

Acknowledgements

The authors thank H. Lundbeck A/S, (Copenhagen, Denmark) for providing the data for the present study.

References


Address for correspondence

Claus Graff
Department of Health Science and Technology,
Aalborg University
Fredrik Bajers Vej 7 E1-209,9220 Aalborg, Denmark
E-mail address: cgraff@hst.aau.dk